BPH-1358 (NSC-50460) (NSC-50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor. With IC50s of 1.8 μM and 110 nM, respectively. And it is active against S. aureus in vitro (MIC ~250 ng/mL)[1][2].

BPH-675 is a bioactive chemical.

BPH-629 is a bioactive chemical.

BPH-628 is a bioactive chemical.

BPH-252 is a bioactive chemical.

BPH-1358 (NSC50460) free base is a potent human undecaprenyl diphosphate synthase (UPPS) and farnesyl diphosphate synthase (FPPS) inhibitor (IC50s: 110 nM and 1.8 μM) and is active against S. aureus in vitro (MIC ~250 ng/mL).

BPH-1358 mesylate (NSC50460 mesylate), a highly effective inhibitor of both human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS), exhibits IC50 values of 1.8 μM and 110 nM, respectively. Additionally, this compound demonstrates potent in vitro activity against S. aureus, with a minimum inhibitory concentration (MIC) approximately 250 ng/mL.

BPH-652 is an S. aureus dehydrosqualene synthase (CrtM) inhibitor (Ki: 1.5 nM; IC50: 100-300 nM for S. aureus pigment formation).

BPH-676 is a bioactive chemical.

BPH-1218 is a SQS inhibitor.

BPH-742 is a bioactive chemical.

BPH-715 inhibits the liver-stage growth of P. falciparum with an IC50 of 10 μM for P. falciparum exoerythrocytic forms in HepG2 cells.

BPH-651 is a CrtM inhibitor.

BPH-830 is a bioactive chemical.

BPH-608 is a bioactive chemical.

BPH-1086 (compound 10) is an inhibitor of IspH. IspH domain fused with ribosomal protein S1 (RPS1) can bind to mRNA or form part of the bacterial ribosome [1] [2].

BPHA (MMP-2/MMP-9 Inhibitor II) is a potent, selective and orally active inhibitor of MMP-2, MMP-9 and MMP-14 with IC50s of 12 nM, 16 nM and 17 nM, respectively.BPHA does not inhibit MMP-1, -3 and -7 (IC50s of 974, >1000 and 795 nM, respectively).BPHA has anti-angiogenic and BPHA has anti-angiogenic and anti-tumor activities.

Dapoxetine hydrochloride (LY-210448 hydrochloride) is a selectivity short-acting serotonin reuptake inhibitor, used for the therapy of premature ejaculation.

Terazosin hydrochloride (Hytrin) , a selective alpha1-antagonist, can treat the benign prostatic hyperplasia (BPH). It also can lower blood pressure, so it is a drug of choice for patients with prostate enlargement and hypertension. It works on the smooth muscle of the bladder and the blood vessel walls by blocking the function of adrenaline.

Dapoxetine (Dapoxetina) is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation.

Sapropterin is a naturally occurring essential cofactor of the three aromatic amino acid hydroxylase enzymes, used in the degradation of amino acid phenylalanine and in the biosynthesis of dopamine, epinephrine, melatonin, norepinephrine, neurotransmitter

Megestrol acetate (BDH1298) is a progestogen with actions and uses similar to those of the progestogens in general. Megestrol acetate also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia.

Fexapotide (NX-1207 free acid) selectively induces apoptosis, effectively reducing prostate volume at the cellular level. This compound is applicable in the research of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) [1] [2] [3].

Alfuzosin hydrochloride (Alfuzosin HCl) is an α1 adrenergic receptor antagonist. It applies to treat benign prostatic hyperplasia (BPH).

Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.

Chlormadinone (free base) is a synthetic steroid hormone and antagonist at androgen and estrogen receptors used to treat BPH and polycystic ovary syndrome. It also promotes osteoblast differentiation and Ca deposition in bone marrow stem cells.

Ozarelix is a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Mechanistically, LHRH antagonists exert rapid inhibition of luteinizing hormone and follicle stimulating hormone with an accompanying rapid decrease in sex hormones and would therefore be expected to be effective in a variety of hormonally dependent disease states including ovarian cancer, prostate cancer, BPH, infertility, uterine myoma and endometriosis. BPH is a non-cancerous enlargement of the prostate that is caused by testosterone. Unlike LHRH agonists, ozarelix has the potential to reduce testosterone just enough to reduce both prostate size and symptoms without the severe side effects associated with a reduction in testosterone.

Tamsulosin ((R)-(-)-YM12617 free base) is an alpha1A adrenergic receptor antagonist for the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin is used to treat difficulty urinating, a common symptom of an enlarged prostate. Tansulosin and other drugs called alpha blockers work by relaxing the neck muscles of the bladder and muscle fibers in the prostate itself, making it easier to urinate.

Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC 50 of 4.2 nM for type II 5α-reductase. The affinity of Finasteride acetate for type II 5α-reductase enzyme was approximately 100-fold higher than that for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia [1] [2] [3].

Grandifloroside shows good antioxidative and potent anti-inflammatory activities, it also exhibits potent inhibitory activity against TNF-α and 5α-reductase, suggests that it might be developed as a source of potent anti-oxidative and anti-inflammatory ag

Bifluranol (BX341) has anti-androgenic activity and has shown significant anti-prostatic activity in in vivo studies for the treatment of benign prostatic hyperplasia (BPH).

Fexapotide triflutate is a caspase and TNF signaling pathway activator used to treat benign prostatic hyperplasia (BPH).

Terazosin-d8 is a deuterated compound of Terazosin. Terazosin has a CAS number of 63590-64-7. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment [1] [2] [3].

Terazosin hydrochloride dihydrate (Heitrin dihydrate) is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH).

Ganoderol B is a potent β ±-glucosidase and angiotensin-converting enzyme inhibitor, with an IC(50) of β ±-glucosidase is 119.8 uM. It may be useful in prostate cancer and benign prostatic hyperplasia (BPH) therapy through suppressing the function of andr

Lapisteride (CS-891) a steroidal 5α-reductase inhibitor is used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia and may be effective in preventing or treating AGA .

Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3].

Silodosin (KAD 3213) is an alpha-Adrenergic Blocker. The mechanism of action of silodosin is as an Adrenergic alpha-Antagonist.

(R)-Terazosin is an active R-enantiomer of Terazosin. (R)-Terazosin is a potent antagonist of α1-adrenoceptor (α1a, α1b and α1d-adrenoceptor with Ki values of 6.51 nM, 1.01 nM and 1.97 nM, respectively).

(S)-Terazosin is an active S-enantiomer of Terazosin. (S)-Terazosin is a potent and high-affinity antagonist of α-adrenoceptor(α1a, α1b and α1d-adrenoceptor with Ki values of 3.91 nM, 0.79 nM and 1.16 nM, respectively).